A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2)

INTRODUCTION: Sepsis remains a major health problem with an increasing incidence, high morbidity and high mortality. Apart from treatment with antibiotics and organ support, no approved specific adjunct therapies currently exist. Adrenomedullin (ADM) is a vasoactive peptide. High plasma concentratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Geven, Christopher, Blet, Alice, Kox, Matthijs, Hartmann, Oliver, Scigalla, Paul, Zimmermann, Jens, Marx, Gernot, Laterre, Pierre-François, Mebazaa, Alexandre, Pickkers, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Intensive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377571/
https://www.ncbi.nlm.nih.gov/pubmed/30782906
http://dx.doi.org/10.1136/bmjopen-2018-024475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377571/
https://www.ncbi.nlm.nih.gov/pubmed/30782906
http://dx.doi.org/10.1136/bmjopen-2018-024475

Ejemplares similares